Methylin Shortage Update: What Patients Need to Know in 2026

If you take Methylin (methylphenidate) for ADHD, keeping up with the medication shortage has been an ongoing challenge. Here's a comprehensive update on where things stand as of 2026, what has changed, and what you can do to protect your access to treatment.

Current Status: Is Methylin Still in Shortage?

Yes — as of June 2026, methylphenidate remains on the FDA Drug Shortage list, where it has been since July 26, 2023. However, the situation has meaningfully improved compared to the peak disruption of 2023 and early 2024. Multiple manufacturers — including Alvogen, Aurobindo, Epic Pharma, Granules Pharmaceuticals, Lannett, Oryza Pharmaceuticals, Sandoz, SpecGx, and Teva — have reported limited or no availability for specific doses at various points in 2026.

The shortage is not uniform. You may be able to find one dose strength but not another. One pharmacy may have stock while another nearby does not. Some extended-release generics remain harder to find than immediate-release formulations.

How Did the Shortage Start?

The ADHD medication shortage began in October 2022 when the FDA confirmed a nationwide Adderall shortage, primarily triggered by manufacturing delays at Teva Pharmaceuticals, the largest U.S. manufacturer of amphetamine mixed salts. The shortage expanded to methylphenidate products by mid-2023 as demand surged across all stimulant classes.

The underlying causes were interconnected: a surge in ADHD diagnoses (accelerated by pandemic-era telehealth expansion), DEA production quotas that couldn't be adjusted quickly enough, global supply chain disruptions affecting raw ingredient imports from Europe, and manufacturing quality issues at several generic manufacturers.

What Has Changed in 2025-2026?

Several developments have improved the situation, though not resolved it:

DEA quota increases: In October 2025, the DEA raised the methylphenidate production quota by approximately 9%, allowing manufacturers to produce more. The DEA also raised d-amphetamine quotas by nearly 25% — the first increase since 2021.

New generic manufacturers: Additional generic manufacturers have entered or re-entered the market, providing more supply sources.

Supply chain stabilization: Global supply chain disruptions from the pandemic era have eased, improving the flow of active pharmaceutical ingredients (APIs).

Partial manufacturer recoveries: Some manufacturers that had zero availability in 2023-2024 have resumed limited production.

Why Does the Shortage Keep Going?

Even with the quota increases and new manufacturers, experts say shortages likely won't fully end because:

DEA quotas are set based on prior-year sales data, which tends to lag behind actual demand growth

ADHD diagnosis rates are still rising, meaning demand continues to grow

Manufacturing ramp-ups take time — increased quotas don't immediately translate to product on pharmacy shelves

Pharmacy stocking limits and purchasing restrictions can create local shortages even when national supply is adequate

What Can Patients Do Right Now?

Here are the most effective strategies for navigating the shortage in 2026:

Start your refill search early. Begin at least 7-10 days before you run out. Schedule II controlled substances typically allow fills when 75-80% of the supply has been used.

Call multiple pharmacies. Availability varies dramatically from pharmacy to pharmacy. Include independents, which often have different supply chains than major chains.

Ask about all manufacturers. Generic methylphenidate is made by multiple companies. One manufacturer's version may be in stock when another's is out.

Talk to your doctor about flexibility. Your doctor may be able to prescribe a different dose strength, formulation, or temporarily switch you to an alternative medication.

Use medfinder to have pharmacies checked on your behalf, so you don't have to make dozens of calls yourself.

Telehealth Access in 2026

The DEA extended COVID-era telehealth prescribing flexibilities through at least the end of 2026. This means providers can continue prescribing Schedule II controlled substances like methylphenidate via telehealth without requiring an in-person visit first. This makes it easier to reach your doctor to discuss shortage-related adjustments.

Looking Ahead

Most experts expect the methylphenidate supply to continue improving gradually through 2026 and into 2027, but intermittent shortages and local stockouts will likely persist. The most reliable way to track current availability is the FDA Drug Shortage Database. And if you're struggling to find your medication, medfinder can help you find which pharmacies near you have it in stock right now.

Want to understand the root causes? See: Why Is Methylin So Hard to Find? [Explained for 2026].